Accelerate Diagnostics, Inc. announced preliminary unaudited revenue results for the year ended December 31, 2023. Preliminary revenue was approximately $12.1 million for the year, compared to $12.8 million in the prior year. While year-over-year revenues for consumable products increased by approximately 5%, overall annual revenue was down year-over-year due to a challenging capital sales environment in all sales regions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 USD | +2.40% |
|
-5.19% | -67.35% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-67.35% | 30.22M | |
+6.37% | 216B | |
+10.21% | 189B | |
+28.22% | 153B | |
+34.42% | 114B | |
+1.18% | 63.2B | |
+19.21% | 54.78B | |
+0.13% | 48.47B | |
-4.16% | 38.88B | |
+2.39% | 36.14B |
- Stock Market
- Equities
- AXDX Stock
- News Accelerate Diagnostics, Inc.
- Accelerate Diagnostics, Inc. Announces Preliminary Unaudited Revenue Results for the Year Ended December 31, 2023